There are currently 110 active clinical trials seeking participants for Endometrial Cancer research studies. The states with the highest number of trials for Endometrial Cancer participants are Texas, New York, California and Ohio.
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
NCT04997096
Recruiting
The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer and if it will improve lower extremity function (function of the legs), lessen chemotherapy-induced peripheral neuropathy (CIPN; numbness or tingling in the hands or feet), and if there is any effect on inflammatory blood markers (the level of a certain marker in the bl... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Ovarian Cancer, Ovarian Carcinoma, Ovarian Cancer Stage IV, Ovarian Cancer Stage III, Ovarian Cancer Stage 3, Endometrial Cancer, Endometrial Cancer Stage
Register for Updates
Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer
NCT03932409
Recruiting
The purpose of this single arm, open label study is to evaluate the feasibility of pembrolizumab combined with radiation administered to the upper part of the vagina (vaginal cuff brachytherapy) followed by three cycles of pembrolizumab and chemotherapy in patients with endometrial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: LSU Health New Orleans, New Orleans, Louisiana +1 locations
Conditions: Endometrial Cancer
Register for Updates
GYNecologic Cancer-Related COGnitive Impairment
NCT06662435
Recruiting
The goal of this study is to test a home-based and patient-tailored cognitive training intervention among gynecologic cancer patients who have completed chemotherapy and who have experienced cancer-related cognitive impairment.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/07/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Ovarian Cancer, Endometrial Cancer, Cervical Cancers, Vulvar Cancers, Uterine Cancer, Cervix Cancer, Ovary Cancer
Register for Updates
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
NCT06710847
Recruiting
Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK4418959 alone or in combination with a PD-1 inhibitor agent can decrease tumor size, is safe, well-tolerated, and how amounts of the study drug decrease in the body over time.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: GSK Investigational Site, Denver, Colorado +3 locations
Conditions: Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer, Endometrial Cancer
Register for Updates
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
NCT05542407
Recruiting
Endometrial cancer (EC) is the fourth most common cancer in United States women, and alarmingly, the frequency and mortality from EC continues to rise, in part due to the obesity epidemic. Obese women with EC have a 6.3-fold increased risk of death from this disease, as compared to their non-obese counterparts. Patients with advanced/recurrent EC are unlikely to be cured by surgery, conventional chemotherapy (paclitaxel + carboplatin is the standard first-line treatment), radiation, or a combina... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Conditions: Endometrial Cancer, Metastasis
Register for Updates
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer
NCT05216432
Recruiting
This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, catalytic subunit alpha (PIK3CA) mutation in blood and/or tumor per local assessment. The study will evaluate RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors. It will als... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/27/2025
Locations: The University of Arizona Cancer Center, Tucson, Arizona +35 locations
Conditions: PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor, Endometrial Cancer
Register for Updates
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT05611931
Recruiting
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v 1.1\]) after completing at least 12 weeks of platinum-based therapy. A total of 220 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/20/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +206 locations
Conditions: Endometrial Cancer
Register for Updates
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
NCT05819892
Recruiting
To learn if chemotherapy given in combination with radiation therapy, followed by maintenance therapy, can help to control endometrial cancer. The safety and effects of this study treatment will also be studied
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Endometrial Cancer
Register for Updates
Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women
NCT06409052
Recruiting
To learn more about women's attitudes toward and knowledge about endometrial cancer and options that might decrease the risk of developing
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/09/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Endometrial Cancer
Register for Updates
A Study of a Weight Loss Intervention in People With Endometrial Cancer
NCT06751589
Recruiting
The researchers are doing this study is to find out whether tirzepatide and semaglutide are practical (feasible) for weight management and blood sugar control for endometrial cancer patients undergoing chemotherapy. The researchers will also look at participants' experience with the study drug, the safety of taking the study drug while receiving chemotherapy, and changes in weight, body fat composition, and blood pressure of participants.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/03/2025
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +6 locations
Conditions: Endometrial Cancer
Register for Updates
Uterine Manipulation During Minimally Invasive Surgery for Early Stage Endometrial Cancer
NCT04586959
Recruiting
This is a prospective, multi-center, randomized non-inferiority phase III study to evaluate if patients undergoing a minimally invasive surgery for early stage uterine cancer have cancer cells in the fluid that is obtained at the time of their surgery when a uterine manipulator is placed versus patients who do not have a uterine manipulator placed.
Gender:
FEMALE
Ages:
Between 18 years and 90 years
Trial Updated:
12/18/2024
Locations: Cleveland Clinic, Cleveland, Ohio +4 locations
Conditions: ENDOMETRIAL CANCER
Register for Updates
Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
NCT05990426
Recruiting
Endometrial cancer is the most common gynecologic cancer and ovarian cancer is the most lethal. The management of both advanced cancers is a combination of chemotherapy and surgery. Standard of care chemotherapeutic treatment for uterine and ovarian cancers is toxic and severely disruptive to the patient's quality of life with the potential for devastating short and long-term side effects. The role of fasting and ketogenic diets has been evaluated in a mixed cancer population and previously show... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/13/2024
Locations: Northwestern Memorial Hospital, Chicago, Illinois
Conditions: Ovary Cancer, Endometrial Cancer, Uterine Cancer
Register for Updates